Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jaguar Animal Health

2.53
+0.03001.20%
Volume:31.35K
Turnover:79.35K
Market Cap:3.35M
PE:-0.02
High:2.59
Open:2.50
Low:2.50
Close:2.50
Loading ...

Jaguar Health Inc. Announces Amendment to Existing Royalty Interest Agreement with Iliad Research, Reducing Outstanding Balance by $4.25 Million

Reuters
·
01 Jul

Jaguar Health Announces Promising Results from Crofelemer Clinical Trials in Intestinal Failure Patients, Plans for Expedited Regulatory Approval

Reuters
·
30 Jun

Jaguar Health Inc. Pursues EMA Approval for Canalevia to Treat General Diarrhea in Dogs Across EU

Reuters
·
25 Jun

Jaguar Health Inc. Extends Maturity Date of Convertible Promissory Notes to January 30, 2026

Reuters
·
25 Jun

Jaguar Health Inc. Announces Progress in Clinical Trials for Crofelemer, Targeting Intestinal Failure in Rare Diseases

Reuters
·
23 Jun

Jaguar Health files to sell 507.4K shares of common stock for holders

TIPRANKS
·
21 Jun

Jaguar Health Inc. to Present at the Emerging Growth Conference for Updates on Near-Term Catalysts

Reuters
·
17 Jun

Jaguar Health Inc. Establishes First Study Site for Canalevia-CA1 Field Study Amid Ongoing FDA Review for Expanded Canine Diarrhea Treatment Approval

Reuters
·
11 Jun

Jaguar Health Pursues FDA Orphan Drug Designation and Expanded Access for Crofelemer in Metastatic Breast Cancer Treatment

Reuters
·
09 Jun

Jaguar Health Inc. to Participate in Virtual Fireside Chat at Lytham Partners' Spring 2025 Spotlight Series

Reuters
·
06 Jun

Jaguar Health Inc. Releases Investor Presentation Highlighting Operational Strategies and Financial Overview

Reuters
·
27 May

Jaguar Health Prices Offering of Shares, Warrants

MT Newswires Live
·
21 May

Jaguar Health prices 246,306 shares at $6.09 in registered direct offering

TIPRANKS
·
21 May

Jaguar Health Inc. Announces $1.5 Million Registered Direct Offering, Issuing 246,306 Shares at $6.09 Each

Reuters
·
21 May

Jaguar Health announces first patient randomized in crofelemer trial

TIPRANKS
·
20 May

Jaguar Health Inc. Launches Phase 2 Clinical Trial for Crofelemer in Pediatric MVID Patients

Reuters
·
20 May

Jaguar Health Initiated at Buy by First Berlin

Dow Jones
·
19 May

Jaguar Animal Health: Mixed Sentiments in Latest Earnings Call

TIPRANKS
·
17 May

Jaguar Health Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
17 May

Jaguar Health Q1 EPS $(16.70) Beats $(18.00) Estimate, Sales $2.21M Miss $2.82M Estimate

Benzinga
·
16 May